UCL Business launches Abcodia
Abcodia (www.abcodia.com), launched by UCL Business in March, is engaged in the validation and discovery of molecular biomarkers for disease diagnosis and screening, having been granted rights to commercialise IP from one of the largest biobanks in the UK created by lead clinical scientists at UCL (University College London). The company aims to make discoveries and improve the diagnosis of many common life-threatening and debilitating diseases, including the major cancers - colon, lung, pancreatic - as well as other conditions such as diabetes, osteoporosis and rheumatoid arthritis.
The biobank comprises serum derived from over 200,000 initially healthy volunteers, and now comprises 500,000 samples, many from volunteers who have provided samples annually. The availability of such large numbers of longitudinal prospective samples, together with data that allows the identification of all major age-related diseases in this cohort, makes this an ideal resource for investigations relating to screening diagnostics.
At the helm of the company is a team of Cambridge biotech entrepreneurs; chief executive Julie Barnes and operations officer Chris Hodkinson have over 45 years experience within the life science R&D and biotechnology industry.
Abcodia is seeking collaborative partners to achieve the best outcomes and is keen to harness a network of molecular technology collaborators and commercial diagnostic partners, as well as collaborations with academia and not-for-profit organisations. Julie Barnes said "With the rapid advances in molecular technologies, this is a very exciting area to be working in right now. I am delighted to be able to lead the company through the early stages of its formation and look forward to working collaboratively with others who share our passion in discovering new molecular biomarkers for many of our common diseases”.
Posted on Monday, 01 August 2011 under Company News University news